Detailed Narrative
Q2 Performance Highlights
Chemours reported Q2 results with net sales slightly below expectations, mainly due to softer residential stationary AC demand in TSS. However, Adjusted EBITDA exceeded expectations, driven by strong operational performance and improved product mix in APM, lower corporate costs, and robust pricing in Titanium Technologies. The company emphasized disciplined commercial execution and the positive impact of its Pathway to Thrive strategy.
TSS Market Dynamics
The Thermal and Specialized Solutions (TSS) business saw solid Q2 results, but net sales were down year-over-year due to lower volumes from reduced aftermarket sales of Opteon blend in North America. This was partially offset by higher pricing in Freon refrigerants. The aftermarket is experiencing destocking after initial channel fill in 2025 related to the U.S. AIM Act, compounded by higher interest rates and a slower housing market. OEM volumes for Opteon grew year-over-year.
Titanium Technologies (TT) Resilience
The TT segment demonstrated strong execution in a challenging, inflationary market. Net sales increased slightly year-over-year, primarily due to global pricing strength, which increased across all regions. Volumes were lower in most key end markets, except for Asian markets (excluding China) and Latin America. Three TiO2 price increases have been announced since December 2025, contributing to approximately a 5% year-to-date price increase.
Advanced Performance Materials (APM) Transformation
APM's Q2 net sales were down year-over-year, mainly due to the SPS Capstone line closure in Q3 2025 and higher costs from a resolved Washington Works outage. However, the Performance Solutions portfolio showed strong momentum, with net sales up 8% year-over-year, driven by demand in data center and semiconductor end markets. Over 40% of Performance Solutions sales are now focused on these high-growth markets, and sales into AI infrastructure represent a high single-digit percentage of total APM and TSS sales.
Balance Sheet and Capital Allocation
Chemours continued to strengthen its financial position through strong cash generation and disciplined capital allocation. The company repaid nearly $270 million of its 2028 euro term loan in Q2, exceeding prior commitments. Progress was also made in resolving legacy litigation, including settlements with the U.S. EPA and West Virginia DEP, which are seen as de-risking the balance sheet and improving financial flexibility.
Pathway to Thrive Strategy
The company is halfway through its Pathway to Thrive strategy, which aims to strengthen its foundation, improve resilience, and create strategic portfolio options. Management highlighted significant progress in de-risking the balance sheet, advancing portfolio transformation, and establishing a stronger operating model through lean principles. The strategy is intended to create greater flexibility for future portfolio actions, with "no portfolio action off the table" to unlock step-change value for shareholders.